B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Disease Behavior

#404

Introduction: B-Lymphocyte Stimulator (BLyS) was recently involved in the regulation of malignant cell survival cancers.

Aim(s): To test BLyS as a new serological marker in the follow-up of patients with neuroendocrine tumors (NET).

Materials and methods: Eighty-one consecutive patients with NET and 56 sex-matched controls enrolled in the study. Patients were classified in two subgroups according to clinical course: evidence of persistent but stable disease or in remission (n=45) and patients with evidence of recurrent disease (n=36). BLyS and Chromogranin A (CgA) serum levels were analyzed by ELISA.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Grimaldi F, Fabris M, Tonutti E, Vescini F, Blasone N,

Keywords: BLyS/BAFF markers, neuroendocrine tumors,